Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Delivery
- Cannabis
- Drug Discovery
- Central Nervous System
- Therapeutic
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 377097
License Grant
Licensee entered into a collaboration with Licensor of the United Kingdom for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (CBD) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC),
License Property
VRP324, the first investigational formulation delivered via the nasal route to enhance CBD transport to the brain. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.
VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.
Field of Use
The rights are to use Licensor’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.
Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC) Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.
Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.
Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.
IPSCIO Record ID: 305651
License Grant
The agreement is for marketing rights in the United States to ET-105. Pursuant to the terms of the License Agreement, Licensee will be responsible for marketing activities and Licensor will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval.
License Property
ET-105 or Lamotrigine for Oral Suspension, is an innovative formulation of lamotrigine to be delivered to patients as an oral suspension. ET-105 is a product candidate for use as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.
Licensor is a pharmaceutical company with a focus in CNS (central nervous system), Dermatology, and Pediatrics.
Field of Use
The NDA has been submitted to the FDA and is under review for the treatment of partial on-set seizures, primary generalized tonic-clonic seizures, and seizures of Lennox-Gastaut syndrome in patients two year of age and older.
IPSCIO Record ID: 204556
License Grant
Licensor grants to Licensee exclusive Worldwide rights to BiPhasix Transdermal Drug Delivery Technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products.
License Property
The term “Product†shall mean any pharmaceutical product, development candidate for human or animal use arising out of the collaboration based on the BiPhasix CBD Intellectual Property Rights.
Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.
BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.
Field of Use
The rights are to BiPhasixâ„¢ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.
The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.
IPSCIO Record ID: 343475
License Grant
Licensee secured global rights from Licensor to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935).
License Property
Soticlestat (TAK-935/OV935) is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve distorted excitatory/inhibitory balance in the brain.
Field of Use
Field of use is for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.
IPSCIO Record ID: 319229
License Grant
United Kingdom Licensor granted to the Licensee an exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, and to engage in a collaborative program utilizing Licensors knowledge, skills and expertise in the clinical development of products and in attracting external funding for such development.
License Property
NES100 is a nanotechnology-based intranasal spray drug product candidate which enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain. NES100 is manufactured using high pressure homogenization and spray drying. The Molecular Envelope Technology (MET) nanoparticles are well tolerated via the nasal route at the dose administered. There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. NES100 is an intranasal device to deliver exogenous enkephalin for the management of acute and chronic pain containing hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan.
Intellectual Property includes but not limited to the US Patent Nos. 8,278,277. This covers lipophilic derivatives of hydrophilic drugs comprising a hydrophilic drug and a cleavable linker as well as methods of treatment using these compositions. In particular the patents relate to compositions of a lipophilic derivative of the hydrophilic neuropeptide Leucine [5]-Enkephalin and an amphiphile compound, where the derivative includes a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine [5]-Enkephalin, and where the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ).
8,278,277 – Delivery of hydrophilic drugs
Licensor is a leader in pharmaceutical nanotechnology. The nanomedicines know-how and proprietary technology platforms provide drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides.
Field of Use
The field of use is for the management of Post-Traumatic Stress Disorder relating to pain. NES100 is an intranasal device and using this product supports the effort among prescribers, regulators, and patients to seek non-addictive treatment options to combat the opioid epidemic.
IPSCIO Record ID: 390198
License Grant
Seller hereby sells, assigns, transfers, conveys and delivers to Buyer, and Buyer does hereby purchase, acquire and accept from Seller, all of Seller’s right, title and interest in, to and under the Purchased Rights. The rights purchased relates to net sales of Lorcaserin.
License Property
Lorcaserin is currently in a Phase 3 clinical trial for Dravet syndrome.
Dravet syndrome is an early childhood-onset CNS disease that results in severe epileptic seizures typically occurring within the first year after birth. Incidence for Dravet syndrome is approximately 115,000 in the United States, and 90% of the associated mutations are de novo (not passed from a parent). Mortality rate for Dravet syndrome patients is higher than general epilepsy patients, with a rate of 15-20% by adulthood. The disease is genetically linked, with 70% to 85% of cases characterized by mutations in the SCN1A gene. Mutations cause defects in the function of the sodium ion channel. Seizures due to Dravet syndrome are typically difficult to control and require life-long treatment.
Purchased Rights means the right to receive one hundred percent (100%) of (i) all milestone payments paid, owed, or otherwise payable by Party C under the Transaction Agreement on or after the date of this Agreement, (ii) all royalties paid, owed or otherwise payable by Party C under Section 8.3 of the Transaction Agreement on or after the date of this Agreement, (iii) all amounts paid, owed or otherwise payable by Party C under the Transaction Agreement on or after the date of this Agreement, (iv) all amounts paid, owed or otherwise payable by Party C of the Transaction Agreement (other than amounts for audit costs) with respect to such milestone payments and/or royalties, (v) all interest paid, owed or otherwise payable by Party C of the Transaction Agreement with respect to such milestone payments and/or royalties, and (vi) all amounts equal to the royalty payable under the Transaction Agreement with respect to all proceeds (including any damages, monetary awards or other amounts recovered, whether by judgment or settlement) deemed Net Sales pursuant to Section 10.3(d) of the Transaction Agreement.
Field of Use
The rights purchased are for the treatment of seizures including Dravet syndrome.
Dravet syndrome is characterized by mutations in the sodium ion channel, the ion channel critical for the generation and propagation of action potentials in neurons, and which ordinarily plays a crucial role inhibitory signaling.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
